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Inflammasome activation in NADPH oxidase defective
mononuclear phagocytes from patients with chronic
granulomatous disease
Abstract
Chronic granulomatous disease (CGD) is an inherited disorder characterized by recurrent infections and
deregulated inflammatory responses. CGD is caused by mutations in subunits of the NADPH oxidase,
an enzyme that generates reactive oxygen species in phagocytes. To elucidate the contribution of the
proinflammatory protease caspase-1 to aberrant inflammatory reactions in CGD, we analyzed cells
isolated from patients with defects in the phagocyte oxidase subunits p22phox, p47phox or gp91phox.
We report that mononuclear phagocytes from CGD patients activated caspase-1 and produced
biologically active interleukin-1beta (IL-1beta) in response to danger signals. Notably, caspase-1
activation and IL-1beta secretion from CGD monocytes was elevated in asymptomatic patients and
strongly increased in patients with noninfectious inflammatory conditions. Treatment with IL-1 receptor
antagonist reduced IL-1 production in monocytes ex vivo and during medical therapy. Our results
identify phagocyte oxidase defective monocytes as a source of elevated IL-1 and provide a potential
therapeutic option to ameliorate inflammatory conditions associated with CGD.
doi:10.1182/blood-2010-01-264218 
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PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Brief report
Inflammasome activation in NADPH oxidase defective mononuclear phagocytes
from patients with chronic granulomatous disease
Felix Meissner,1 Reinhard A. Seger,2 Despina Moshous,3 Alain Fischer,3 *Janine Reichenbach,2 and *Arturo Zychlinsky1
1Department of Cellular Microbiology, Max Planck Institute for Infection Biology, Berlin, Germany; 2Division of Immunology/Haematology/BMT, University
Children’s Hospital Zurich, Zurich, Switzerland; and 3Division of Paediatric Haemato-Immunology and Rheumatology, Assistance Publique–Hopitaux de Paris,
Hoˆpital Necker-Enfants Malades, University Paris Descartes, Paris, France
Chronic granulomatous disease (CGD) is
an inherited disorder characterized by
recurrent infections and deregulated in-
flammatory responses. CGD is caused by
mutations in subunits of the NADPH oxi-
dase, an enzyme that generates reactive
oxygen species in phagocytes. To elucidate
the contribution of the proinflammatory
protease caspase-1 to aberrant inflamma-
tory reactions in CGD, we analyzed cells
isolated from patients with defects in the
phagocyte oxidase subunits p22phox,
p47phox or gp91phox. We report that
mononuclear phagocytes from CGD pa-
tients activated caspase-1 and produced
biologically active interleukin-1 (IL-1)
in response to danger signals. Notably,
caspase-1 activation and IL-1 secretion
from CGD monocytes was elevated in
asymptomatic patients and strongly in-
creased in patients with noninfectious
inflammatory conditions. Treatment with
IL-1 receptor antagonist reduced IL-1 pro-
duction in monocytes ex vivo and during
medical therapy. Our results identify
phagocyte oxidase defective monocytes
as a source of elevated IL-1 and provide a
potential therapeutic option to ameliorate
inflammatory conditions associated with
CGD. (Blood. 2010;116(9):1570-1573)
Introduction
Chronic granulomatous disease (CGD) is a genetically heterogeneous
primary immunodeficiency caused by defects in phagocyte nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase subunits.1
This phagocyte oxidase generates superoxide by transferring electrons
from NADPH to molecular oxygen and consists of the catalytic subunit
gp91phox, structurally stabilized by p22phox, and of the regulatory
subunits p47phox, p40phox, p67, and RAC.2 Loss-of-function muta-
tions in any of these components abrogate oxidase activity and
compromise host immunity against certain bacteria and fungi. However,
there is now increasing evidence for excessive inflammation in CGD
even in the absence of infectious agents with increased frequency and
severity of granulomatous inflammatory reactions, notably colitis.3-5
Inflammasomes are implicated in host protection and a variety
of inflammatory diseases by regulating the maturation of the
caspase-1 dependent cytokines interleukin-1 (IL-1) and IL-18 in
response to a broad range of danger signals.6 However, the function
of the phagocyte oxidase during caspase-1–mediated proinflammatory
responses is controversial, and the implications of such responses
for CGD pathology are poorly understood.7
Here we evaluated the contribution of the phagocyte oxidase to
the exuberant inflammatory responses associated with CGD, by
analyzing inflammasome activation in cells from CGD patients. We
show that mononuclear phagocytes from CGD patients activate
caspase-1 and produce biologically active IL-1 in response to
danger signals. Notably, IL-1 release from monocytes was elevated
in CGD patients and could be controlled by IL-1 receptor
antagonist (IL-1Ra) ex vivo and during treatment with anakinra.
Our results implicate caspase-1–mediated inflammation in CGD
pathogenesis and may help designing therapies to ameliorate
inflammatory conditions in these patients.
Methods
Human monocytes and macrophages
All experiments with human samples were done after informed consent was
received from the patients and parents in accordance with the Declaration of
Helsinki, as part of a protocol approved by the institutional review board of the
University Children’s Hospital Zurich. Blood from CGD patients, heterozygous
carriers, and healthy donors (supplemental Tables 1-2, available on the Blood
Web site; see the Supplemental Materials link at the top of the online article) was
drawn on ethylenediaminetetraacetic acid (EDTA) and diluted in phosphate-
buffered saline (PBS) supplemented with 2mM EDTA, pH 7.2 (PBS/EDTA). Up
to 30 mL of blood were layered on 15 mL of Histopaque (density 1.077 g/mL)
and centrifuged at 400g and 21°C for 30 minutes. The resulting interphase
containing peripheral blood mononuclear cells (PBMCs) was isolated and
washed with PBS/EDTA at 400g and 21°C for 10 minutes. Platelets were
removed by repeated centrifugation at 200g for 15 minutes. Monocytes were
isolated from PBMCs by depletion of nonmonocytes (negative selection) using
the Monocyte Isolation Kit II (Miltenyi Biotec; 130-091-153) according to the
manufacturer’s instructions. Monocytes were then cultivated in RPMI containing
penicillin/streptomycin and 5% human serum (Sigma-Aldrich). Monocytes were
used for experiments the next day. For experiments with monocyte-derived
macrophages, monocytes were differentiated into macrophages in RPMI contain-
ing penicillin/streptomycin and 5% human serum with 5 ng/mL macrophage
colony stimulating factor (M-CSF; Miltenyi Biotec) for 6 days. Purity of
monocytes and macrophages was more than 96% as determined by fluorescent-
activated cell sorter using anti-CD14 antibody (Miltenyi Biotec; 130-080-701).
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Caspase-1 activation assays
Monocytes were stimulated with 500 ng/mL lipopolysaccharide (LPS; from
Salmonella typhimurium; Alexis Biochemicals) or 100 g/mL monosodium
urea (MSU). Monocyte-derived macrophages were primed with 500 ng/mL
LPS for 3 hours before addition of the indicated inflammasome activators:
adenosine triphosphate (ATP; 2mM) from Roche; nigericin (2M) and
silica (100 g/mL) from Sigma-Aldrich; MSU (100 g/mL) and prepared
as described.8 Caspase-1 activity was assessed by fluorescent-activated cell
sorter using caspase-1 FLICA (Immunochemistry Technologies) according
to the manufacturer’s instructions. Human mature IL-1, IL-1, tumor
necrosis factor, and IL-6 were determined in cell supernatants and IL-1
precursor in cell lysates by enzyme-linked immunosorbent assay (BD
Biosciences and R&D Systems, respectively). To interfere with IL-1 ex
vivo, 1 to 10M YVAD-cmk (Alexis Biochemicals) or 1 to 10 ng/mL
anakinra (Amgen/Biovitrum) was used.
Medical treatment with IL-1Ra
Treatment of a patient with IL-1Ra was performed after informed consent
was received from the patients and parents by daily subcutanous injection
of 15 mg of anakinra for 8 days, before conditioning for bone marrow
transplantation.
Results and discussion
To analyze the impact of the phagocyte oxidase on caspase-1–
mediated inflammation we tested human mononuclear phagocytes
from asymptomatic CGD patients, heterozygous carriers, and
healthy controls for their responses to inflammasome activation
(supplemental Tables 1-2). Interestingly, macrophages with a
defect in any of the phagocyte oxidase subunits p22phox, p47phox,
or gp91phox responded to danger signals such as extracellular ATP,
the pore-forming toxin nigericin, crystals of uric acid (monosodium
urea, MSU), or silica with robust caspase-1 activation (Figure
1A-B). CGD macrophages also secreted biologically active IL-1
in response to these activators at levels comparable with healthy
controls, indicating that a functional phagocyte oxidase is dispens-
able for caspase-1–mediated inflammatory responses in human
macrophages (Figure 1C-E).
Because monocytes have a specific function in innate immunity and
activate caspase-1 by a unique mechanism such as a single Toll-like
receptor 4 (TLR4) stimulation, we next analyzed IL-1 production in
CGD monocytes.9 Notably, caspase-1 activation and IL-1 secretion
were elevated in unstimulated CGD monocytes and in response to LPS
or MSU (Figure 2A-D, supplemental Figures 1-2). Consistently, IL-1
levels were substantially reduced ex vivo by inhibiting caspase-1 with a
specific inhibitor or by blocking IL-1 signaling with the naturally
occurring IL-1Ra (supplemental Figures 1,3).10,11
Based on these findings, we wondered whether the hyperinflamma-
tory condition in symptomatic CGD patients involves a deregulation of
IL-1 and analyzed monocytes from patients with granulomatous colitis,
a common gastrointestinal manifestation in CGD that involves inflam-
mation in the absence of infectious agents.5 Intriguingly, both, unstimu-
lated and LPS-stimulated monocytes from symptomatic CGD patients
showed strongly increased caspase-1 and IL-1 levels, indicating that
caspase-1 is active during severe colitis in CGD despite the loss of
phagocyte oxidase function (Figure 2E, supplemental Figure 4).12
Symptomatic CGD patients with clinical symptoms distinct from colitis
also show increased IL-1 production and could be counteracted by
inhibition of caspase-1 or IL-1 signaling ex vivo (supplemental Figure
4). In agreement with previous studies, further analysis confirmed a
differential preactivation of CGD monocytes as characterized by
increased levels of tumor necrosis factor, IL-6, and IL-1 precursor that
may reflect the clinical situation of the individual patient (supplemental
Figure 5).13
Our observations prompted us to test IL-1Ra (anakinra/Kinert)
for the treatment of noninfectious colitis in CGD. Interestingly,
within 1 week of daily administration of anakinra, IL-1 production
in monocytes dropped substantially, suggesting that deregulated
IL-1 production is associated with the aberrant inflammatory
manifestation associated with CGD (Figure 2F-G). However,
clinical improvement only consisted of reduced frequency of
abdominal pain crises and not of a reduced frequency of stools per
Figure 1. Macrophages from CGD patients activate caspase-1
and secrete mature IL-1. (A-B) Caspase-1 activation in monocyte-
derived macrophages determined by a fluorescent inhibitor of
active caspase-1 (FLICA). (A) Lipopolysaccharide (LPS)–primed
() macrophages from a chronic granulomatous disease (CGD)
patient (p22) and a healthy control (C1) stimulated for 1 hour with
adenosine triphosphate (ATP) or for 6 hours with silica crystals
(SiO2) or monosodium urea (MSU) crystals. Numbers above
bracketed lines indicate percentage of cells with active caspase-1.
(B) Active caspase-1 in macrophages from 3 CGD patients with
the indicated mutations and 3 healthy controls (C1-C3) quantified
by caspase-1 FLICA. (C-E) Macrophages from the indicated CGD
patients and healthy donors stimulated with LPS plus ATP,
nigericin (NI), SiO2, or MSU. The production of mature interleukin-1
(IL-1) at the indicated time points was determined by enzyme-
linked immunosorbent assay. Data are representative of 6 experi-
ments with cells from at least 5 different CGD patients (error bars
indicate SEM of triplicate wells).
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day, possibly due to slow resolution of the chronic inflammatory
lesions during the short time of treatment with anakinra.
The impact of the phagocyte oxidase during inflammasome
activation is controversial due to use of different model systems.
Because phagocytosis activates the phagocyte oxidase, it was
suggested that a functional phagocyte oxidase is particularly
important for caspase-1 activation induced by particles.6,14 Our data
indicate that both inflammasome stimuli that require phagocytosis,
such as MSU or silica, as well as those that do not require
phagocytosis, like ATP or nigericin, activate caspase-1 indepen-
dently of the phagocyte oxidase. Our study thus confirms that
macrophages from CGD patients respond to inflammasome activa-
tion similarly to macrophages from gp91phox deficient mice,
which also activate caspase-1 robustly.8,15,16 Notably, the results
presented here contrast with those of previous studies based on
pharmacologic inhibition of the phagocyte oxidase or p22phox
knockdown in THP-1 cells.17-19 In fact, pharmacologic inhibition
and enzymatic degradation of reactive oxygen species can act
oppositionally on inflammasome activation, warranting a careful
consideration for the use of these inhibitors.15,19 Accordingly,
enzymes that maintain the redox homeostasis rather potentiate
IL-1 processing and inflammation.15,20 The discrepancy of results
obtained by individual experimental designs underscores the
importance of studying human pathology using unmanipulated
primary cells from healthy donors and diseased patients.
More importantly, our study together with a recent report by
van de Veerdonk et al21 identifies CGD monocytes as a source of
increased IL-1 and is consistent with the observation that inflamma-
tory markers are elevated in CGD.13,22,23 Along with other recent
findings, our results extend the initial conception of the phagocyte
oxidase primarily as a source of harmful mediators by suggesting
an anti-inflammatory function via inflammasome regulation in
monocytes.5,24,25 Because IL-1 is a pleiotropic cytokine involved in
the induction of other inflammatory molecules and the regulation
of lymphocyte function, our data open up new potential strategies
for therapeutic intervention by targeting IL-1 for inflammatory
noninfectious complications in CGD.11
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